Pfizer considers raising bid for AstraZeneca

Pfizer Inc is planning to return with a higher bid for British rival AstraZeneca Plc before the US drugmaker considers going hostile, Bloomberg reported on Monday, citing people familiar with the matter.

The new offer will increase the value modestly above the current 50 pounds ($84.36) per share level while increasing the cash portion, two people familiar with the matter told Bloomberg.

Both Pfizer and AstraZeneca could not be reached for comment outside of business hours.

On May 2, AstraZeneca turned down a sweetened Pfizer cash and stock offer that valued the British company at 63 billion pounds ($106 billion).

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Sebi’s proposal to bring clarity to merger moves is a welcome step

    Market regulator Sebi is reportedly planning changes in rules governing merger and acquisition of companies in India.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Arun Kumar Jain

Prosperity mantra across the ages

The economic prosperity of a nation rests upon its ability ...

Kuruvilla Pandikattu SJ

Can we pop a pill for compassion?

Can altering brain chemistry make us more sensitive to inequality? ...

Gautam Gupta

Fashion forward for e-commerce industry?

Looks like the e-commerce industry is taking a leaf out ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture